Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UWD-06
- Development stage
- Preclinical
- Lead developer
- Wondercel Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
UWD-06 is an allogeneic chimeric antigen receptor T-cell (CAR-T) therapy currently in preclinical development by Wondercel Therapeutics for the treatment of breast cancer. As an allogeneic, or "off-the-shelf," cell therapy, UWD-06 is derived from healthy donor T-cells rather than the patient's own cells, which may allow for more rapid administration and reduced manufacturing costs compared to autologous therapies. While the specific molecular target of the CAR has not been publicly disclosed, the program aims to utilize the cytotoxic capabilities of engineered T-cells to selectively identify and eliminate malignant breast cancer cells.
Beyond the preview
Go deeper on UWD-06.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UWD-06.